Cheongdam The Cell's joint programme and realistic staging
Quick answer
Intra-articular SVF aims to calm synovial inflammation, relieve pain and slow cartilage loss. Most likely to benefit are early to moderate osteoarthritis (Kellgren-Lawrence grade 2–3) with joint space remaining. In advanced bone-on-bone disease, knee replacement remains the clearly superior standard.
Knee osteoarthritis is not only worn cartilage: it involves synovial inflammation and subchondral bone change. That is why anti-inflammatory strategies can reduce pain even when the X-ray looks unchanged — so temper expectations about cartilage regrowth more than expectations about pain and function.
Good planning starts with weight-bearing X-rays and alignment assessment. With significant varus deformity loading one compartment, injections alone rarely suffice because the mechanical overload continues; osteotomy or bracing may belong in the plan.
Always pair the injection with physiotherapy, quadriceps strengthening and weight reduction where relevant. The osteoarthritis literature is consistent that these deliver large, low-cost symptom gains; cell therapy belongs inside that plan, not as a shortcut around it.
Before committing, ask what SVF dose is used, whether injection is ultrasound-guided, whether WOMAC or KOOS scores are recorded before and after, and what the 3-, 6- and 12-month follow-up looks like. Those answers separate structured care from package selling.
It depends on stage and response; many patients review at three months before deciding on repeat treatment or a change of plan.
Hyaluronic acid mainly lubricates for a short period, whereas cell therapy targets the inflammatory environment inside the joint — slower onset, but aimed further upstream.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Joints & immunity